Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kuvan in pediatric PKU with elevated phenylalanine
NCT01732471Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2012
- Primary completion
- Oct 2013
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sapropterin in phenylketonuria (PKU), sponsored by Merck KGaA. Primary endpoint: Percentage of Participants With Response to Kuvan Treatment at Day 8. Started Nov 2012; status: completed.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT01732471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732471.